UVA LVG Seed Fund Portfolio

BrightSpec, Inc.

BrightSpec, Inc. is a life science instrumentation company founded in 2012 and based on the research and patented technologies of UVA Chemistry Professor, 2017 Innovator of the Year, and the company's current Chief Scientist, Brooks Pate, Ph.D. 

For the last seven years, BrightSpec has been shaping the field of analytical chemistry and introduced an entirely new measurement technique into one of the most conservative fields in science: molecular rotational resonance spectroscopy. In 2016, the company brought the first product line of spectrometers based on molecular rotational resonance (MRR) spectroscopy to market. 

BrightSpec's recently announced Series B financing will support corporate development and a new product launch, and was followed by their announcement of a technology asset acquisition from BioTools, Inc. that will continue to grow their portfolio. 

Ceres Nanosciences, Inc.

Ceres Nanosciences Inc. (“Ceres”) is engaged in the research, development, and commercialization of innovative sample preparation products and diagnostic tests, based on its proprietary Nanotrap® particle platform. The Nanotrap® particles capture, enrich and preserve the most valuable biomarkers, enabling early and accurate detection of diseases such as cancer, cardiac, neurological, and infectious diseases, resulting in improved patient outcomes and reduced health care costs.

510Kardiac Devices, Inc.

510 Kardiac is an early stage medical device company developing novel technologies for cardiovascular surgical procedures. The company was co-founded by Dr. Scott Lim, an interventional cardiologist and the Director of the Advanced Cardiac Valve Center at the University of Virginia Health System and the company’s current CEO, Jaime Sarabia, a mechanical engineer with more than 18 years of experience in medical device ventures.

Mission Secure

Mission Secure, Inc. (MSi) provides unprecedented control system cyber security visibility AND protection. The patented* MSi Platform has been conceived, developed and deployed over the past seven years by a world class team of cyber security professionals, control system engineers, PhDs, military and business experts. Our team is committed to protecting critical physical assets, and the control systems that monitor and operate them, in defense, energy and transportation.


Discovered by UVA Professor of Cell Biology and Ophthalmology Dr. Gordon Laurie, TearSolutions' first-in-class therapy is a synthetic form of the protein lacritin which targets the root causes of dry-eye disease. 


TypeZero Technologies, Inc.

DexCom, Inc., a publicly traded company and leader in continuous glucose monitoring for people with diabetes acquired TypeZero Technologies in September 2018. This acquisition marks the first exit for the UVA LVG Seed Fund. 

The world leader in clinically tested automated insulin delivery solutions, TypeZero Technologies is a digital health and personalized medicine company dedicated to revolutionizing the treatment and management of diabetes. TypeZero is combining next-generation data science techniques, proven metabolic models, and modern engineering practices to develop customized analytics tools and blood glucose control solutions to help people with diabetes improve their health and lives. TypeZero’s current solutions include a smartphone-based automated insulin delivery system, therapy optimization tools for health care providers, and advisory applications for smart insulin pens. To learn more, visit www.typezero.com.